Gray Comprehensive Credit Evaluation Of Small And Medium Pharmaceutical Companies Based On AHP And Entropy Method

With the development of social and economic，basic industries，as people’slivelihood-the pharmaceutical industry, the increasingly high degree of concern.People are increasingly concerned about their own health, but also pay more attention tothe credit standing of the pharmaceutical companies, especially small and medium-sizedpharmaceutical companies. Countries continue to timely introduction of various rulesand regulations governing and regulating the pharmaceutical market, banks andinvestors are increasingly concerned about the credit standing of the emerging small andmedium-sized pharmaceutical companies to reduce investment risk. Domestic creditevaluation system obsolete, evaluation methods are not specific enough and mature,weak relevance and applicability. So we need to change the research ideas, looking fornew ways, and constantly try to introduce new interdisciplinary outstandingachievements in scientific research, combined with China’s specific national conditionsand social conditions conducive to objective, fair design a credit evaluation system,fairly small and medium-sized pharmaceutical enterprises in China and method, whichregulate the pharmaceutical market, improve the financing environment, and promoterapid, healthy and sustainable development has an important and positive.The characteristics of small and medium-sized pharmaceutical enterprises of China:First, China’s pharmaceutical industry is a technology-intensive industries that requirehigh technical content, innovation and technology capital investment, with a highthreshold, high input, high-risk, long cycle characteristics; Second, small andmedium-sized enterprises. The logo is a small scale, immature, high-speed growth anduncertainty. This article is a combination of both features, designed to contain thefinancial and non-financial factors, a combination of static and dynamic indicators,repayment ability and credit history situation of small and medium-sizedpharmaceutical enterprise credit evaluation index system, breaking the existingdomestic credit rating agency considerations the incompleteness of the heavy financialinformation, industry-specific, without regard to the status quo policy and nationalconditions and factors to improve the accuracy of the credit evaluation results. The content of this study are as follows:First of all, We introduce the Research and theoretical basis for China’s small andmedium-sized pharmaceutical companies, credit risk and gray system; Secondly, thepaper through a lot of literature reading, survey, experts and scholars access to thecombination of methods to determine the credit rating of the small and medium-sizedpharmaceutical companies in China index system, which indicators is re-determinedaspects, combined with AHP hierarchy analysis method and entropy rights law,combination Weighting filtered evaluation index, the index weight weight not onlyreflect the subjective experience of the experts, but also reflect the data’s owncharacteristics, and thus minimize the risk the existing index weight design unduereliance on the lack of expertise; once again, according to China’s small andmedium-sized pharmaceutical companies set up a short time, the lack of raw data,inadequate sample size, information disclosure is not complete many uncertaintiesfeatures, gray system theory toit is more appropriate to assess the credit status of smalland medium-sized pharmaceutical companies; Finally, the credit risk of the small boardof the Shenzhen Stock Exchange All18small and medium-sized pharmaceuticalcompanies an empirical study to verify the feasibility of the method.